Human Pheromone Sciences Q2
This article was originally published in The Rose Sheet
Executive SummaryFragrances Realm and Inner Realm entering South Korean market as part of a long-term initiative to expand distribution into Asia, firm says. Disappointing sales in the U.S. and Far East coupled with delayed order shipments resulted in net loss of $118,000 in the second quarter compared to net income of $12,000 the prior year period, San Jose, Calif. company reports. Net sales declined 51.9% to $269,000. Despite negative short-term results, "we firmly believe in the viability and long-term value of our fragrance and toiletry products," company maintains...
You may also be interested in...
Most of the foreign OTC drug firms targeted in latest warnings FDA published, including the GUM oral care brand manufacturer, were placed on import alert due to GMP violations. Each was inspected by FDA during June, July or May 2019, when the agency was wrapping up an initiative to inspect all previously uninspected drug manufacturers.
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
The US agency is engaged with an ethylene oxide (EtO) sterilizer in Illinois that has temporarily closed to determine if there are any potential risks to the medical device supply chain. While the plant shut down about a month ago, regulators have only recently been made aware of the decision, which resulted from a law passed last year by the state legislature.